nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.09.2022 | editorial

CAR-T cells—Real-time experience applying CAR-T cells—What we have learned so far

verfasst von: Univ.-Prof. Dr. Hildegard Greinix

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Excerpt

CD19-targeted chimeric antigen receptor-engineered(CAR)‑T cells are novel therapies showing great promise for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma, mantle cell lymphoma, and follicular lymphoma. EMA-approved and commercially available CAR‑T cell products have been used successfully by qualified CAR‑T cell centers worldwide and these real world data compare favorably to pivotal study results with overall response rates (ORR) and complete response rates (CR) ranging from 51–93% and 40–64%, respectively [1‐9]. …

Nächster Artikel Molecular profiling leading to personalized cancer treatment

Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B‑cell lymphoma. N Engl J Med. 2019;380(1):45–56. https://doi.org/10.1056/NEJMoa1804980.CrossRefPubMed

Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T‑cell therapy in refractory large B‑cell lymphoma. N Engl J Med. 2017;377(26):2531–44. https://doi.org/10.1056/NEJMoa1707447.CrossRefPubMedPubMedCentral

Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B‑cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52. https://doi.org/10.1016/S0140-6736(20)31366-0.CrossRefPubMed

Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116. https://doi.org/10.1126/scitranslmed.aaf8621.CrossRefPubMedPubMedCentral

Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T‑cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–42. https://doi.org/10.1056/NEJMoa1914347.CrossRefPubMedPubMedCentral

Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J Clin Oncol. 2020;38(27):3095–106. https://doi.org/10.1200/JCO.19.02103.CrossRefPubMedPubMedCentral

Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B‑cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119–28. https://doi.org/10.1200/JCO.19.02104.CrossRefPubMedPubMedCentral

Gauthier J, Gazeau N, Hirayama AV, et al. Impact of CD19 CAR T‑cell product type on outcomes in relapsed or refractory aggressive B‑NHL. Blood. 2022;139(26):3722–31. https://doi.org/10.1182/blood.2021014497.CrossRefPubMed

Fusaroli M, Isgrò V, Cutroneo PM, et al. Post-marketing surveillance of CAR-T-cell therapies: Analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf. 2022; https://doi.org/10.1007/s40264-022-01194-z.CrossRefPubMedPubMedCentral

10.

Locke FL, Miklos DB, Jacobson DA, et al. Axicabtagene ciloleucel as second-line therapy for large B‑cell lymphoma. N Engl J Med. 2022;386(7):640–54. https://doi.org/10.1056/NEJMoa2116133.CrossRefPubMed

11.

Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B‑cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–308. https://doi.org/10.1016/S0140-6736(22)00662-6.CrossRefPubMed

12.

Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–16. https://doi.org/10.1056/NEJMoa2024850.CrossRefPubMed

13.

Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Abstract 549. In: 63rd ASH Annual Meeting & Exposition. 2021.

14.

Kamel YM. CAR‑T therapy, the end of a chapter or the beginning of a new one? Cancers. 2021;13(4):853. https://doi.org/10.3390/cancers13040853.CrossRef

15.

Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T‑cell therapy. Ann Oncol. 2021;32(1):34–48. https://doi.org/10.1016/j.annonc.2020.10.478.CrossRefPubMed

16.

Steffin DHM, Muhsen IN, Hill LC, et al. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022;140(1):16–24. https://doi.org/10.1182/blood.2022015728.CrossRefPubMed

17.

Hsieh E, Myers R, Yates B, et al. Low rate of subsequent malignant neoplasms following CAR T‑cell therapy. Blood Adv. 2022; https://doi.org/10.1182/bloodadvances.2022008093.CrossRefPubMed

18.

Amini L, Silbert SK, Maude SL, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19(5):342–55. https://doi.org/10.1038/s41571-022-00607-3.CrossRefPubMed

19.

Greinix HT, Attarbaschi A, Girschikofsky M, et al. Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T‑cell therapy: position statement of the Austrian CAR‑T Cell Network. memo. 2020;13:27–31. https://doi.org/10.1007/s12254-020-00582-4.CrossRef

20.

Charrot S, Hallam S. CAR‑T cells: future perspectives. HemaSphere. 2019;3(2):e188. https://doi.org/10.1097/HS9.0000000000000188.CrossRefPubMedPubMedCentral

21.

Rallis KSA, Hillyar CRT, Sideris M, Davies JK. T‑cell-based immunotherapies for haematological cancers, part A: a SWOT analysis of immune checkpoint inhibitors (ICIs) and bispecific T‑cell engagers (BiTes). Anticancer Res. 2021;41(3):1123–41. https://doi.org/10.21873/anticanres.14870.CrossRefPubMed

Titel: CAR-T cells—Real-time experience applying CAR-T cells—What we have learned so far
verfasst von: Univ.-Prof. Dr. Hildegard Greinix
Publikationsdatum: 01.09.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-022-00830-9

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities

Neoadjuvant treatment in gastric cancer

Neoadjuvant treatment in non-small-cell lung cancer—the earlier, the better

Neoadjuvant treatment of pancreatic ductal adenocarcinoma

Neoadjuvant treatment for solid tumors—the earlier, the better

Molecular profiling leading to personalized treatment in breast cancer